Moleculera receives patent for diagnostic process

Published: Tuesday, November 7, 2017 By: Staff Reports Source: NewsOK

Oklahoma City's Moleculera Labs Inc., an autoimmune neurobiology company, said Monday that a key patent has been issued covering the company's method of identifying whether someone's neurologic or psychiatric symptoms could be caused by an autoimmune dysfunction.

The patent covers Moleculera's methods of diagnosing pediatric acute-onset neuropsychiatric syndrome (PANS) and pediatric autoimmune neuropsychiatric disorder associated with Streptococci infection (PANDAS).

Read the full story at

Back to top